Updated from April 28

Millennium Pharmaceuticals ( MLNM) shares fell more than 5% Thursday after the company late Wednesday reported a narrower loss but lower-than-expected revenue in the first quarter.

The Cambridge, Mass.-based biotech company had a net loss of $40.6 million, or 13 cents a share, compared with a loss of $137.9 million, or 47 cents a share a year ago. Revenue rose to $92.6 million from $81.7 million in the year-ago period. Excluding items, the company lost 7 cents a share.

The consensus forecast was for a loss of $65 million, or 20 cents a share, on revenue of $106.9 million, according to Thomson First Call.

Shares fell 99 cents, or 5.7%, to $16.29, having touched a 52-week high of $19.87 in February.

Sales of its Velcade cancer treatment, which was approved by the Food and Drug Administration in the second quarter of last year, were $29.6 million.

Millennium also held to its previous forecast for a full-year loss of $255 million to $285 million on a GAAP basis and a $175 million to $200 million loss on a non-GAAP basis. Analysts are forecasting a loss of $175 million.

Research and development costs fell to $96.3 million from $126.8 million a year ago.

Millennium said Tuesday that it had won regulatory approval of Velcade in the European Union. Johnson & Johnson ( JNJ ) will market the drug outside of the U.S. with Millennium receiving royalties on sales.

If you liked this article you might like

Spain to Play Netherlands for World Cup

Spain to Play Netherlands for World Cup

Wal-Mart: Analysts' Upgrades, Downgrades

Wal-Mart: Analysts' Upgrades, Downgrades

Netherlands Advances to World Cup Final

Netherlands Advances to World Cup Final

Apple: Analysts' Upgrades, Downgrades

Apple: Analysts' Upgrades, Downgrades

World Markets Mostly Lower Monday

World Markets Mostly Lower Monday